Viewing StudyNCT00193479



Ignite Creation Date: 2024-05-05 @ 11:57 AM
Last Modification Date: 2024-10-26 @ 9:17 AM
Study NCT ID: NCT00193479
Status: COMPLETED
Last Update Posted: 2022-03-03
First Post: 2005-09-12

Brief Title: Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab in Large B-Cell Non-Hodgkins Lymphoma
Sponsor: SCRI Development Innovations LLC
Organization: SCRI Development Innovations LLC

Organization Data

Organization: SCRI Development Innovations LLC
Class: OTHER
Study ID: SCRI LYM 28
Study Type: None
Study Domain: None
Study Link: None
Lead Sponsor: SCRI Development Innovations LLC
Lead Sponsor Class: OTHER
Responsible Party: None
Responsible Party Title: None
Responsible Party Type: SPONSOR
Responsible Party Affiliation: None
Old Name: None
Old Organization: None

Collaborators

Name Class
Genentech Inc INDUSTRY
Amgen INDUSTRY